Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in
resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
Phase:
Phase 1
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc. Institut de Recherches Internationales Servier